Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders for Enanta Pharmaceuticals, Inc., held on February 11, 2016. The filing details the voting outcomes for director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal No. 1: Election of Class III Directors
- Ernst-Gunter Afting: Re-elected with 11,256,742 votes for, 1,352,530 votes withheld, and 2,291,029 broker non-votes.
- Stephen Buckley, Jr.: Re-elected with 11,270,674 votes for, 1,338,598 votes withheld, and 2,291,029 broker non-votes.
- Proposal No. 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of PricewaterhouseCoopers LLP for the fiscal year ending September 30, 2016.
- Votes For: 13,668,349
- Votes Against: 1,231,520
- Abstain: 432
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the definitive proxy statement filed on January 13, 2016, for detailed biographies of the re-elected directors.
- Confirm the total shares outstanding to calculate the percentage of votes cast for each proposal.
- Review the upcoming 10-K or 10-Q filings for the financial metrics absent from this 8-K.